Current and emerging therapies in nonalcoholic fatty liver disease

Seminars in Liver Disease

Volumn 28, Issue 4, 2008, Pages 396-406

  Kashi, Maryam R ^a   Torres, Dawn M ^b   Harrison, Stephen A ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Fatty liver; Metabolic syndrome; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Thiazolidinediones (TZDs)

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETAINE; CLOFIBRATE; EZETIMIBE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PROTEIN 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; METFORMIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CALORIC RESTRICTION; CELL PROTECTION; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; GASTRECTOMY; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE BYPASS; LEG EDEMA; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; MONOTHERAPY; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIOXIDANTS; BARIATRIC SURGERY; BODY MASS INDEX; CANNABINOIDS; CHOLAGOGUES AND CHOLERETICS; COMORBIDITY; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LACTONES; LIFE STYLE; METFORMIN; OBESITY; PIPERIDINES; PYRAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; WEIGHT LOSS;

EID: 56649117397     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0028-1091984     Document Type: Review

References (83)

1. Zelman S. The liver in obesity. AMA Arch Intern Med 1952;90:141-156
2. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958;34:686-693
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438
4. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-1090
5. Singh SP. Non-alcoholic fatty liver disease: the unfolding monster? J Gastroenterol Hepatol 2006;21:199-201
6. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455
7. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26
8. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845
9. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56:1760-1769
10. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007;91:1125-1149
11. Bloom SR, Kuhajda FP, Laher I, et al. The obesity epidemic: pharmacological challenges. Mol Interv 2008;8:82-98
12. Pereira MA, Kartashov AI, Ebbling CB, et al. Fast food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005;365:36-42
13. Kechagias S, Ernersson A, Dahlqvist O, et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008;57:649-665
14. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 1998;47:1643-1649
15. Nielsen SJ, Popkin BM. Changes in beverage intake between 1977 and 2001. Am J Prev Med 2004;27:205-209
16. Elwood PC, Pickering JE, Fehily AM. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. J Epidemiol Community Health 2007;61:695-698
17. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-999
18. Cave M, Deaciuc I, Mendez C, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007;18:184-195
19. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419
20. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005;43:1060-1066
21. Ueno T, Sugawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107
22. Tock L, Prado WL, Caranti DA, et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. Eur J Gastroenterol Hepatol 2006;18:1241-1245
23. Harrison SA, DiBisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003;63:2379-2394
24. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003
25. Marchesini G, Brizi M, Bianchi G, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-894
26. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-544
27. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004;20:23-28
28. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525
29. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38(4):1008-1017
30. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
31. Aithal GP, Aithal GP, Thomas JA, et al. A randomized double blind, placebo controlled trial of one year of pioglitazone in non-diabetic subjects with non-alcoholic steatohepatitis. Hepatology 2007;46(suppl 1):295A
32. Thomas JA, Kaye P, et al. A randomized double blind, placebo controlled trial of one year of pioglitazone in nondiabetic subjects with non-alcoholic steatohepatitis. Hepatology 2007;46:295A
33. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized, placebo-controlled FLIRT trial. Gastroenterology 2008;135:100-110
34. Nissen SE, Wolski K. The effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular issues. N Engl J Med 2007;356:2457-2471
35. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007;41:2014-2018
36. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes mellitus. JAMA 2007;298:194-206
37. Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181
38. Tushuizen ME, Brunck MC, Pouwels PJ, et al. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-1017
39. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008;134:1137-1147
40. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007;47:135-141
41. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007;11:597-613
42. Cohen DE, Anania FA, Chalasani NNational Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
43. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-1463
44. Vuppalanchi R, Chalasani N. Statins for hyperlipidemia in patients with chronic liver disease: are they safe? Clin Gastroenterol Hepatol 2006;4:838-839
45. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292
46. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-196
47. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-778
48. Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003;48:2182-2186
49. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-1467
50. Bauditz J, Schmidt HH, Dippe P, Lochs H, Pirlich M. Nonalcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid. Am J Gastroenterol 2004;99:959-960
51. Vajro P, Mandato C, Franzese A, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 2004;38:48-55
52. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734-738
53. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-419
54. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485-2490
55. Barak AJ, Beckenhauer HC, Junnila M, Tuma DJ. Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993;17:552-555
56. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717
57. Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Altern Med Rev 2002;7:276-291
58. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-628
59. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-644
60. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98:926-930
61. Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 2007;27:1152-1155
62. Woods SC. Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. Am J Med 2007;120:S19-S25
63. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonibant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397
64. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiovascular risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775
65. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134
66. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006;368:1660-1672
67. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58
68. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histologic analysis with weight loss. Hepatology 2004;39:1647-1654
69. Mathurin P, Gonzalez F, Kerdraon O, et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006;130:1617-1624
70. Furuya CK, de Oliveira CPMS, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007;22:510-514
71. Mattar SG, Velcu LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005;242:610-620
72. Barker KB, Palekar NA, Bowers SP, et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006;101:368-373
73. de Almeida SR, Rocha PRS, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006;16:270-278
74. Clark JM, Alkhuraishi ARA, Solga S, et al. Roux-en-Y gastric bypass improves liver histology in patients with nonalcoholic fatty liver disease. Obes Res 2005;13:1180-1186
75. Mottin CC, Moretto M, Padoin AV, et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005;15:788-793
76. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007;17:486-492
77. Csendes A, Smok G, Burgos AM. Histologic findings in the liver before and after gastric bypass. Obes Surg 2006;16:607-611
78. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone for the treatment of nonalcoholic steatohepatitis. Hepatology 2004;39:188-196
79. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazaone in the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115
80. Lutchman G, Modi A, Kleiner DE, et al. The effect of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-429
81. Idilman R, Mizrak D, Corapcioglu D, et al. Insulin sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-208
82. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-226
83. Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 2008;28:407-426